NOVEL PHARMACOLOGICAL ACTIVITIES OF CURCUMA LONGA EXTRACTS

The invention relates to novel pharmacological activities of Curcuma longa extracts as antiproliferative and photosensitizing agent and to their use in the treatment of proliferative pathologies such as psoriasis and in the reduction of plasmatic fibrinogen and the apolipoprotein B/apoliprotein A-I...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	RAMIREZ BOSCA, ANA, DIAZ ALPERI, JOAQUIN, PAMIES MIRA, DAVID, PARDO ZAPATA, JOSE, CARRION GUTIERREZ, MIGUEL ANGEL, QUINTANILLA ALMAGRO, ELISEO, BERND, AUGUST, SEMPERE ORTELLS, JOSE MIGUEL
Format:	Patent
Sprache:	eng ; fre ; spa
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention relates to novel pharmacological activities of Curcuma longa extracts as antiproliferative and photosensitizing agent and to their use in the treatment of proliferative pathologies such as psoriasis and in the reduction of plasmatic fibrinogen and the apolipoprotein B/apoliprotein A-I quotient without altering other coagulation parameters. Nuevas actividades farmacológicas de los extractos de Curcuma Longa como agente antiproliferativo y fotosensibilizante y su uso en las patologías proliferativas como la psoriasis, así como reductora del Fibrinógeno plasmático y del cociente Apolipoproteina B/apoliproteina A-I, sin alterar los demás parámetros de la coagulación. L'invention concerne de nouvelles activités pharmacologiques des extraits de Curcuma Longa en tant qu'agent antiprolifératif et photosensibilisant, ainsi que leur utilisation dans le traitement des pathologies prolifératives, telles que le psoriasis. L'invention concerne également l'activité desdits extraits comme agent de réduction du fibrinogène plasmatique et du rapport apolipoprotéine B/apolipoprotéine A-I, sans modification des autres paramètres de la coagulation.